News
XOMA
24.76
+6.18%
1.44
Weekly Report: what happened at XOMA last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at XOMA last week (0212-0216)?
Weekly Report · 02/19 12:01
Health Care Sector Update for 02/16/2024: SRPT, XOMA, KNTE, CORT
NASDAQ · 02/16 18:53
HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target
Benzinga · 02/16 18:41
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
XOMA Corporation agreed to acquire Kinnate Biopharma Inc (NASDAQ:KNTE) for $2.3352 per share. Kinnate is a clinical-stage precision oncology company focused on developing cancer-targeted therapies. The acquisition is expected to close in April 2024. XOMA stock is up 11.45% on Friday.
Benzinga · 02/16 17:55
Strategic Acquisitions and Royalty Income Streams Justify Buy Rating for Xoma
TipRanks · 02/16 16:25
Xoma Corp Secures Merger with Kinnate Biopharma Inc.
TipRanks · 02/16 14:22
Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share
Seeking Alpha · 02/16 13:23
Weekly Report: what happened at XOMA last week (0205-0209)?
Weekly Report · 02/12 11:48
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about Xoma Corp Del through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Corporation is a biotechnology royalty aggregator. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The Company has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. Its royalty portfolio includes AFM13, AFM24, AB002 (proCase/E-WE thrombin), AB023 (xisomab, 3G3), AB054, AZD2936, AV-299 (ficlatuzumab), BAY1213790 (osocimab), CMP-001 (vidutolimod), Lysosomal Storage Disorders Enzymes, COM902, DAY101 (tovorafenib), vosaroxin, INCAGN1876, INCAGN1949, INCAGN02390, INCAGN2385, JNJ-63723283 (cetrelimab), MK-4830, MT-0169, CFZ533 (iscalimab), VPM087 (gevokizumab), NIS793, NIR178, G03-52-01, ebopiprant, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ358, RZ402, faricimab (faricimab-svoa), TAK-079 (mezagitamab), Aldoxorubicin, and Arimoclomol. The Company's subsidiaries include XOMA Technology Ltd., XOMA (US) LLC, and XOMA UK Limited.